Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use

Katarzyna Gutfreund, Wojciech Bienias, Anna Szewczyk, Andrzej Kaszuba, Katarzyna Gutfreund, Wojciech Bienias, Anna Szewczyk, Andrzej Kaszuba

Abstract

Topical calcineurin inhibitors (TCI) are a relatively new class of drugs used in dermatology. There are two drug forms available - tacrolimus 0.03% or 0.1% ointment and 1.0% pimecrolimus cream. The drugs act by inhibiting synthesis of proinflammatory cytokines. The only approved indication for using TCI is treatment of atopic dermatitis. The TCI may be used as an alternative therapy to corticosteroids. Tacrolimus is used to treat moderate-to-severe atopic dermatitis, pimecrolimus - mild-to-moderate atopic dermatitis. Topical calcineurin inhibitors do not cause skin atrophy and the drug absorption through the skin is minimal. The TCI have been well-studied, their efficacy was evaluated in a number of vast, long-term studies. The anti-inflammatory potency of tacrolimus ointment is similar to a corticosteroid with moderate activity, while the latter is clearly more active than pimecrolimus cream. Topical calcineurin inhibitors significantly relieve pruritus in atopic eczema.

Keywords: pimecrolimus; tacrolimus; topical calcineurin inhibitors.

References

    1. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135:574–80.
    1. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol. 2002;16:100–14.
    1. Tharp MD. Calcineurin inhibitors. Dermatol Ther. 2002;15:325–32.
    1. Surber C, Itin P, Büchner S. Clinical controversy on the effect of topical cyclosporin: what is the target site? Dermatology. 1992;185:242–5.
    1. Brown MM, Brown GC, Brown HC, et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009;127:146–52.
    1. Pacor ML, Biesi D, Carleto A, et al. Topical cyclosporine in the treatment of oral pemphigus. Minerva Stomatol. 1998;47:183–6.
    1. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46:228–41.
    1. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract. 2005;59:969–74.
    1. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol. 2007;8:157–73.
    1. Silny W, Sadowska A, Dańczak-Pazdrowska A, Polańska A. Application of tacrolimus in the treatment of skin diseases other than atopic dermatitis. Postep Derm Alergol. 2011;28:41–5.
    1. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy. 2009;64:276–8.
    1. Healy E, Bentley A, Fidler C, et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164:387–95.
    1. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–60.
    1. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol. 2004;32:224–6.
    1. Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatments with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150:1174–81.
    1. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol. 2007;157:861–73.
    1. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001;137:747–50.
    1. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol. 2002;138:1259–60.
    1. Pitarch G, Torrijos A, Mahquijes L, et al. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. Acta Derm Venereol. 2006;86:64–5.
    1. Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29–35.
    1. Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36:1812–8.
    1. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol. 2005;53:602–9.
    1. Undre NA, Moloney FJ, Ahmadi S, et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult with moderate to severe atopic dermatitis. Br J Dermatol. 2009;160:665–9.
    1. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211:174–87.
    1. Mandelin JM, Rubins A, Remitz A, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. Int J Dermatol. 2012;51:104–10.
    1. Hofman T, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child. 2006;91:905–10.
    1. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554–62.
    1. Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol. 2007;87:54–61.
    1. Reitamo S, Rustin M, Harper J, et al. 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. A 4 year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159:942–51.
    1. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
    1. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;61:375–81.
    1. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142:155–62.
    1. Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 2004;208:365–72.
    1. Paller AS, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is mor effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810–22.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren